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Abstract
Objectives—A high body mass index (BMI) in middle-age or a decrease in BMI at late-age has 
been considered a predictor for the development of Alzheimer's disease (AD). However, little is 
known about the BMI change close to or after AD onset.
Methods—BMI of participants from three cohorts, the Washington Heights and Inwood 
Columbia Aging Project (WHICAP; population-based) and the Predictors Study (clinic-based), 
and National Alzheimer's Coordinating Center (NACC; clinic-based) were analyzed 
longitudinally. We used generalized estimating equations to test whether there were significant 
changes of BMI over time, adjusting for age, sex, education, race, and research center. 
Stratification analyses were run to determine whether BMI changes depended on baseline BMI 
status.
Results—BMI declined over time up to AD clinical onset, with an annual decrease of 0.21 
(p=0.02) in WHICAP and 0.18 (p=0.04) kg/m2 in NACC. After clinical onset of AD, there was no 
significant decrease of BMI. BMI even increased (b=0.11, p=0.004) among prevalent AD 
participants in NACC. During the prodromal period, BMI decreased over time in overweight(BMI 
≥25 and <30) WHICAP participants or obese (BMI≥30) NACC participants. After AD onset, BMI 
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tended to increase in underweight/normal weight (BMI<25) patients and decrease in obese 
patients in all three cohorts, although the results were significant in NACC study only.
Conclusions—Our study suggests that while BMI declines before the clinical AD onset, it 
levels off after clinical AD onset, and might even increase in prevalent AD. The pattern of BMI 
change may also depend on the initial BMI.
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INTRODUCTION
The role of weight or BMI in predicting Alzheimer's disease (AD) has been widely explored 
in epidemiological studies. In general, these studies have found higher mid-life weight or 
BMI is associated with increased risk for the development of AD [1-7]. In late life, higher 
baseline BMI has been shown to be related with a decreased risk of AD, while faster 
declining of BMI or weight in late life is associated with higher risk of AD [8-16].
Weight loss was included as a “clinical feature consistent with the diagnosis of AD” in the 
original version of the National Institute of Neurological and Communicative Disorders and 
Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) 
Work Group report [17]. As weight loss is frequently observed in AD patients in clinical 
practice, it has been claimed or assumed that the decrease of BMI or weight loss continues 
after AD onset. This is often hypothesized to be due to loss of the sense of taste and/or 
smell, depression, decreased ability to prepare meals, dental problems, forgetting to eat or 
neurobiological changes related to accumulating AD pathology [18]. Even more, weight loss 
is often used as a clinical aid in the differential diagnosis of AD from other related 
conditions such as frontotemporal dementia (which is often accompanied by weight gain). 
However, there have been few reports from large population-based studies confirming 
weight loss in AD [19-28]. Furthermore, previous studies [19-28] were based on prevalent 
patients only, while BMI change during the period around diagnosis has not been examined. 
This would require tracking BMI in incident AD patients. Finally, most previous studies 
used weight but not BMI as a measurement of adiposity.
Using BMI assessments from participants in three, well-established, large cohorts of AD 
patients, we examined BMI change over time during the prodromal (shortly pre-clinical 




Predictors study—The recruiting and evaluation procedures of the Predictors Study have 
been described in more detail elsewhere [29]. Briefly, participants in the Predictors Study II 
were recruited and studied at four sites: Columbia University, New York; Johns Hopkins 
University, Baltimore; Massachusetts General Hospital, Boston; and Paris, France. 
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Enrollment required a modified Mini-Mental State Examination (mMMSE) score of ≥30 
(maximum = 57) which is equivalent to a score of approximately 16 or more on the Folstein 
MMSE [30]. All participants met DSM-III-R criteria for primary degenerative dementia of 
the Alzheimer type and NINCDS-ADRDA criteria for probable AD at enrollment. 
Neurologic and mental status examinations were conducted at study entry and repeated at 6-
month intervals. Subjects who had at least two BMI evaluations were included in the current 
study. The study was reviewed and approved by the participating institutions' review boards, 
and written informed consent was obtained from all subjects.
Washington Heights/Hamilton Heights Inwood Columbia Aging Project 
(WHICAP)—The WHICAP participants were identified (via ethnicity and age stratification 
processes) from a probability sample of Medicare beneficiaries aged 65 or older, residing in 
northern Manhattan [31]. Briefly, at entry, a physician elicited each participant's medical and 
neurological history, and conducted standardized physical and neurological examinations. 
Each participant was also administered a structured in-person interview, including an 
assessment of health and function, and a neuropsychological battery [32]. The diagnosis of 
any type of dementia or its absence was based on standard research criteria, using all 
available information at a consensus conference of physicians, neurologists, 
neuropsychologists and psychiatrists. Participants were followed every 1.5 years, repeating 
the baseline examination and consensus diagnosis [33, 34]. For the diagnosis of probable or 
possible AD, the criteria of the NINCDS-ADRDA were used. All WHICAP participants 
who met the criteria for probable or possible AD at baseline (prevalent AD) or follow-up 
(incident AD) and had at least two BMI assessments were included in the study. The 
Columbia University Institutional Review Board has reviewed and approved this project. All 
individuals provided written informed consent.
National Alzheimer's Coordinating Center (NACC)—The study population was 
composed of subjects from the National Alzheimer's Coordinating Center (NACC) Uniform 
Data Set (UDS) [35], gathered prospectively from 33 Alzheimer's Disease Centers (ADCs) 
(29 active and 4 inactive) between September 2005 and June 2011. Subjects underwent 
annual clinical exams, which included cognitive and functional testing. Standardized forms 
were used at all Centers and informed consent was given by all subjects and their 
informants. Research using the NACC database was approved by the Institutional Review 
Board at the University of Washington. To be eligible for the current study, the NACC 
participants had to meet the criteria for probable or possible AD at baseline (prevalent AD) 
or follow-up (incident AD), have at least two BMI assessments, and be age 65 or older at the 
first visit with BMI assessment.
BMI measurement
BMI was measured in a similar way in three cohorts. With the participant standing, body 
weight was measured to the nearest 0.1 kg with a balance scale, and height was measured 
without shoes to the nearest 0.5 cm. BMI was calculated as weight in kilograms divided by 
height in square meters [kg/m2]) [36].
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Age at baseline (years) and education (years) were used as continuous variables. Participants 
were assigned to one of three race groups: White, Black (African American), or Other based 
on self-report. Race was used as a dummy variable with White as the reference. Sex was a 
dichotomous variable with male as the reference. Weight-gaining medication included 
neuroleptics and other antipsychotics[37], weight-losing medicine included cholinesterase 
inhibitors[38]. Ever use of these medication was considered as a dichotomous variable with 
never-used as the reference. Type of residence was categorized as regular home or 
retirement community (as reference) vs. any assisted living facilities including assisted 
living/boarding home/adult family home, rehabilitation center, skilled nursing facility, or 
nursing home. APOE ε4 was used as a dichotomous variable, with carrying 1 or 2 ε4 allele 
as 1 and not carrying ε4 allele as 0 (the reference).
Statistical analyses
To fully describe the dynamic change of BMI over time along the AD course, primary 
analyses were conducted separately for the following analytical groups: 1) Before AD onset: 
BMI before AD onset among incident AD participants, 2) On and after AD onset: BMI on 
and after AD onset among incident AD participants, and 3) Prevalent AD: BMI among 
prevalent AD participants, presumably representing a later stage of the disease. All three 
analytical groups were available for WIHCAP and NACC, while the Predictors study (by 
design) included prevalent AD patients only. Time of the first BMI evaluation among each 
analytical group was treated as the baseline visit.
Baseline characteristics of patients were described. Follow-up time was years from the 
baseline BMI assessment to the last BMI assessment. Generalized estimating equations 
(GEEs) with BMI as the outcome variable and time from baseline as the main predictor 
variable were used to determine if there was a significant decrease (negative β coefficient of 
time) or increase (positive β coefficient of time) of BMI over time. The GEE models were 
initially unadjusted (Model 1) and then adjusted (Model 2) for covariates including age, 
gender, race, and education. In Model 3, research center and type of residence (both for 
Predictors study and NACC study only), and medication use were additionally adjusted, as 
previous studies have found these factors may affect the modes of weight loss in AD 
patients [39].
To examine whether rate of change in BMI depended on initial BMI status (underweight and 
normal weight BMI<25, overweight BMI ≥25 and <30, and obese BMI≥30), we included an 
interaction term (time × initial BMI status) in Model 3. Stratification analysis by initial BMI 
status was done subsequently to estimate the rate of BMI change in each subgroup.
Sensitivity analysis—To examine change in BMI up to the time of AD diagnosis, we 
included the BMI assessment at the same visit of AD onset in the ‘before onset’ group, 
rather than in the ‘on or after onset’ group. The NACC cohort includes subjects who were 
less than 65 years old when they entered the study but were included in the primary analyses 
if they had the first BMI assessments at or after age 65. Sensitivity analyses were done by 
limiting NACC subjects to those who were 65 or older at their first visit to NACC. As 
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APOE ε4 genotype has been shown to be associated with weight loss in patients with AD 
[40], we further adjusted for APOE ε4 genotype in a final Model 4 that also included all the 
covariates of Model 3. We also examined whether rate of change in BMI depended on 
APOE ε4 genotype by including the interaction term of time × APOE ε4 genotype in the 
Model 4.
All analyses were conducted using PASW Statistics (IBM, Chicago, IL). All p values were 
based on 2-sided tests. The significance level was set at 0.05 for all tests.
RESULTS
Characteristics of the study population
Demographic characteristics of the analytic samples are presented in Table 1. All baseline 
characteristics are evaluated at the first BMI visit where the subject met all inclusion criteria. 
Overall, the populations of Predictors study and NACC study shared similar demographic 
characteristics: they were both in late 70's at the baseline BMI assessment, the majority of 
the study population was White, they both included slightly more females than males, and 
participants they had approximately college level education. The WHICAP population was 
multi-ethnic, including mainly Hispanics, but also Black and White. The WHICAP 
population also had lower education, and included more females than males.
Change of BMI over time
BMI during the prodromal (pre-onset) phase of incident AD—In models adjusted 
for basic covariates, we found a significant decrease of BMI before the clinical disease onset 
in WHICAP (Table 2, Model 2, β= −0.21, p=0.02; i.e., about 0.21 kg/m2 decline per year, or 
approximately 0.6 kg decline per year for people with a height of 1.7 m; Figure 1). We 
found an almost identical magnitude of annual BMI decline before clinical onset in the 
NACC data (Table 2, Model 2, β= −0.18, p=0.04; Figure 1).
BMI on and after the onset of incident AD—During the on average 4.67 years of 
follow-up after AD onset, we found that BMI did not seem to change in incident AD 
patients of WHICAP or NACC (Table 2, Model 2, β= −0.06, p=0.51; Figure 1) in WHICAP 
participants. Similarly, during the on average 1.88 years of follow-up after AD onset in 
NACC participants, we found that BMI did not change (β=0.09, p=0.24; Figure 1).
BMI among prevalent AD participants—We found a marginally significant increase 
(Table 2, Model 2, β= 0.17, p=0.06) in BMI among prevalent AD participants of the 
Predictors study, but the increase was no longer significant after adjusted for covariates. In 
prevalent AD participants of WHICAP, though, the BMI did not change (Table 2, Model 2, 
β= −0.07, p=0.50; Figure 1) Among NACC participants who entered the study with 
prevalent AD, the BMI increased significantly (Table 2, Model 2, β= 0.11, p=0.004; Figure 
1).
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BMI change over time by initial BMI status
BMI during the prodromal (pre-onset) of incident AD—In WHICAP, we found no 
difference in rate of BMI decline according to initial BMI status (interactions between initial 
BMI status and time: β for overweight*time= −0.06, p=0.56; and β for obesity*time= −0.07, 
p=0.74). In NACC, we found that obese subjects experienced a faster decline of BMI than 
normal weight subjects prior to AD onset, with a significant interaction between initial BMI 
and time (β for obesity*time interaction= −0.93, p=0.02). Subsequent stratification analysis 
showed that BMI decreased significantly over time in obese subjects only (Table 3, β= 
−0.82, p<0.0001).
BMI on and after the onset of incident AD—In WHICAP, subjects who were obese at 
baseline had a faster decline of BMI (β for obesity*time =−0.5, p=0.002) compared to 
normal-weight subjects. In NACC, we found a significant interaction between initial BMI 
and time (β for overweight*time= −0.25, p=0.004; and β for obesity*time= −0.62, 
p<0.0001). Subsequent stratification analysis showed that BMI increased in underweight/
normal-weight subjects, was stable in originally overweight subjects, and continued to 
decrease in originally obese subjects (Table 3).
BMI among prevalent AD participants—In Predictors study, there was a significant 
interaction between initial BMI status and time, with overweight (β for overweight*time= 
−0.38, p=0.015) and obese (β for obese*time= −0.59, p=0.001) subjects having less increase 
of BMI overtime compared to underweight/normal weight subjects. Indeed, we saw a 
marginally significant increase of BMI (β=0.21, p=0.06) in underweight/normal weight 
patients, while a stable BMI in overweight (β = −0.06, p=0.59) and tended to decrease in 
obese (β = −0.21, p=0.14) subjects. Similar to the Predictors study findings, there was a 
significant interaction between initial BMI status and time, with overweight (β for 
overweight*time= −0.21, p<0.0001) and obese (β for obese*time= −0.55, p<0.0001) 
subjects had less increase of BMI overtime in the NACC study. More interestingly, the 
overall pattern and magnitude of BMI change over time in NACC prevalent AD patients 
were very similar to those of the Predictors study: subjects with an initial underweight/
normal profile had a significant increase of BMI (β=0.21, p<0.0001) and obese subjects had 
a significant decrease of BMI (β= −0.26, p=0.001), while the overweight subjects 
maintained a stable BMI (β = 0.01, p=0.82). In WHICAP, BMI status at baseline did not 
modify the rate of BMI change over time.
Sensitivity analyses
When the visit of AD onset was categorized as ‘before onset’ rather than ‘after onset’, the 
results were similar to those in the primary analysis (data not shown). When analysis was 
limited to NACC subjects who were 65 years or older at their first visit, the results did not 
change materially (data not shown). When APOE ε4 genotype was additionally adjusted, the 
results did not change much (Model 4 in Table 2). There seemed to be no interaction 
between APOE ε4 genotype in the WHICAP and NACC cohorts. However, in Predictors’ 
study, there was a significant decline of BMI in APOE e4 non-carriers (B=−0.44, P=0.006) 
while a non-significant increase of BMI (b=0.13, p=0.24) was found in APOE e4 positive 
subjects (p for interaction = 0.03).
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In this longitudinal analysis of data from three large cohorts, we found BMI decreased prior 
to clinical AD onset. Following the onset of clinical AD, there was no longer a significant 
decrease of BMI. Furthermore, BMI seemed to increase in prevalent AD patients.
Our findings of decreasing BMI before onset of AD are consistent with existing 
epidemiological studies showing that weight loss may precede the diagnosis of dementia 
[8-16]. The mechanism for late-life decline of BMI preceding AD diagnosis is unknown, but 
likely to be associated with the underlying pathological change of dementia. Brain areas that 
participate in weight control (i.e., mesial temporal cortex, MTC) [41] are affected during the 
preclinical dementia phase, thereby leading to weight loss. Disrupted release of hormones 
and neuropeptides in predementia can also interact with brain centers to induce 
physiological responses leading to weight reduction before the onset of dementia [42]. 
Weight loss may also result from predementia apathy [43], reduced olfactory function [44], 
difficulty in eating (both feeding apraxia and impaired swallowing) [45], and/or inadequate 
nutrition [46] due to cognitive impairment. Alternatively, it is possible that weight loss 
might also be a potential risk factor for developing AD via several potential biological 
mechanisms [47]. For example, long-term weight loss could contribute to a deficiency of 
some micronutrients such as antioxidative vitamins or fatty acids [46], which have been 
quite often associated with reduced risk of AD [48]. In addition, recent evidence indicates 
that leptin, an adipokin produced by subcutaneous and visceral adipose tissue, could be 
neuroprotective by enhancing neuronal survival, protecting against oxidative damage, and 
promoting the proliferation of hippocampal progenitor cells [49]. Thus, persons who lose 
weight may have a decrease in leptin and thus have a lower level of neuroprotection.
A few earlier prospective studies have reported that weight loss frequently occurs in the AD 
patients [19-25]. However, more recently, several studies found AD patients may not 
necessarily experience weight loss. One study found that 79 AD and 26 non-demented 
institutionalized subjects maintained stable body weights throughout their institutional stay 
over 48 months [26]. In another prospective study of 395 prevalent AD patients, weight loss 
of 4% or more in 1 year was observed in about one third of the study sample [39], indicating 
that the majority of patients did not experience significant weight loss over one year. In 
another study, about 22% of the 362 AD patients lost 5% of their weight per year, but AD 
patients were also more likely to gain ≥5% of their initial weight than controls [27]. Finally, 
a study following 50 AD patients for 30 months found that 26 of them gained weight and 24 
lost weight [28]. In our study, we did not find an overall significant loss or gain of weight 
among AD patients during the first several years following the diagnosis. When the BMI 
change was examined in prevalent AD patients, presumably representing a later stage of 
AD, we found a trend of increase of BMI in two clinic-based studies, or a stable BMI in the 
population-based WHICAP study. Thus, our data do not support the earlier reports of weight 
loss or BMI drop in AD patients, but rather echoed the more recent studies by noticing that 
BMI does not drop in prevalent AD patients.
We also found overweight or obese participants had a decline of BMI prior to AD diagnosis, 
but those who were normal/underweight did not. This could be due to a ‘floor effect’, as 
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subjects who were normal/underweight may not have as much weight to lose as those who 
were obese or overweight. The overall increase of BMI in prevalent AD patients may be 
driven by the large number of normal/underweight subjects, who started to gain weight 
shortly after diagnosis. Obese patients, in contrast, may continue to lose weight even long 
after the diagnosis, although the rate of decrease slowed down compared to before onset. It 
is unclear why the BMI change pattern after AD onset differs by the initial BMI. One 
hypothesis is that once patients are diagnosed with AD, especially in clinic-based patients 
cohorts (NACC and Predictors study), they may receive more intensive health care, such as 
increased supervision and more careful monitoring of weight and food intake. Therefore, 
after AD onset, obese patients may lose weight because they may receive a better controlled 
amount of foods from caregivers, while the normal/underweight patients may receive 
increased foods intake, both in an effort to help the patient reach a normal weight. It can be 
noted (by examining the β values in the models) that, no matter what initial BMI status is, 
the trend seems to be that the decrease of BMI gradually slows down over time, or even 
switches to an increase at certain stage for subjects with low BMI. This suggests that before 
the AD onset, those physiological changes such as reduced olfactory function, apathy, and 
others may play key roles in the BMI decrease, while at a later stage when the patients are 
more severely impaired, factors such as lower mobility due to functional impairments or use 
of weight-increase medications begin to play a more important role, contributing to the 
increase of BMI.
We found additional adjustment of APOE status did not change the results much. We also 
found BMI decreased in APOE ε4 negative but not in ε4 positive prevalent patients 
according to the data from Predictors’ study. However, no such difference was found in the 
WHICAP or NACC cohorts. Very few studies have examined the relationship of APOE ε4 
status and weight loss, and the results seemed to be inconsistent. One study found APOE ε4 
was associated with associated with weight loss[40], while other studies found the presence 
of the 4 allele was not associated with weight loss[9, 50]. Further studies are needed to 
examine whether APOE genotype is associated with change of BMI or weight.
Our study has certain limitations. Although we considered many potential confounding 
factors that can influence weight in our analyses, it is still possible that our results are 
explained by residual confounding, including those due to other medications, dose and 
duration of medication use, physical activity, and other disease conditions that could affect 
mobility and thus less energy expenditure or dietary caloric intake. We also lack detailed 
information about family support structure, which could influence eating patterns and, 
hence, weight loss or gain.
Confidence in our findings is high for several reasons. To our knowledge, this is the first 
study to describe trends of BMI change among AD patients, especially at different stages of 
the disease. The current study contains both population-based and clinic-based cohorts and 
has large sample size overall or in each cohort. The WHICAP cohort is a multi-ethnic 
sample, including a large number of Hispanics. The diagnosis of AD in all three cohorts was 
based on comprehensive assessment and standard research criteria. We adjusted for some 
potential confounders including many demographic and clinical factors, and these factors 
were carefully collected according to standard research protocol in all three cohorts. It is not 
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uncommon that associations noted in single studies are not observed in subsequent 
investigations. Thus, one of the most important elements of this report is the replication of 
the BMI change pattern in more than one cohort.
Overall, the current study confirmed prior evidence regarding an observable decrease of 
BMI prior to AD onset, but found stability or an increase in BMI among patients after 
clinical diagnosis of AD. Our findings, if replicated in future studies, may have important 
implications for AD diagnosis, prognosis, or management. Our findings of BMI change after 
AD onset suggest that a longitudinal tracking of BMI may be one of the useful factors to 
consider for early diagnosis of AD. Monitoring the BMI may also useful for prognosis. For 
example, a recent study among 414 patients with a diagnosis of probable AD found that 
weight loss was predictive of subsequent rapid cognitive decline[51], which has consistently 
been reported to predict worse prognosis. Finally, monitoring weight and BMI may also help 
caregivers plan for the nutritional needs of patients at different points of the illness.
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Figure 1. GEE-predicted BMI during the course of follow-up among three cohorts of 
Alzheimer's disease (AD) patients
Figure 1 shows GEE-predicted BMI (y-axis) during the course of follow-up in years (x-
Axis) among three cohorts of Alzheimer's disease (AD) patients. The figure is derived from 
models that are adjusted for age, sex, ethnicity, and education. Duration of follow-up is 
based on the average number of follow-up years in each phase (before onset, after and on 
AD onset, prevalent AD), separately for the three cohorts. Dotted lines indicate non-
significant trends while solid lines indicate significant increase or decrease of BMI
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Table 1
Characteristics of study populations.
Predictors Study WHICAP NACC
Prevalent AD Before AD onset On or 
after AD 
onset




Total number of 
subjects, N
190 176 144 118 593 600 3191
Total number of visits, 
N
1025 508 377 329 1563 1616 9396
Number of visits, 
mean(SD)
5.39 (2.78) 2.89 (0.95) 2.62 (0.84) 2.79 (0.88) 2.64 (0.85) 2.69 (0.88) 2.94 (1.10)
Follow-up time⫲, years, 
mean(SD; range)
3.4 (2.2) 4.78 (2.67) 4.67 (2.75) 4.17 (2.4) 1.88 (0.94) 1.88 (0.96) 2.34 (1.26)
Age at initial BMI visit, 
years
76 (7.7) 78.9 (6.4) 80.8 (6.1) 81.9 (6.6) 78.7 (8.5) 79.3 (7.1) 77.9 (6.8)
Female, N (%)mean(SD) 114 (60) 130 (73.9) 101 (70.1) 85 (72) 312 (53) 294 (49) 1668 (52)
Education, years 13.8 (3.5) 8.5 (4.8) 5.8 (4.8) 5.5 (4.2) 14.9 (3.3) 15.4 (3.1) 14.0 (3.8)
Race, N (%) / / / / / /
    White 142 (96) 38 (22) 11 (8) 9 (8) 514 (87) 523 (87) 2593 (81)
    Black 17 (4) 48 (27) 28 (19) 33 (28) 58 (10) 49 (8) 401 (13)
    Others / 90 (51) 103 (72) 76 (64) 20 (3) 28 (5) 190 (6)
BMI at initial visit, 
kg/m2
25.4 (4.2) 27.6 (5.8) 26.9 (5.1) 26.6 (4.8) 25.8 (4.1) 26.0 (4.4) 26.3 (4.5)
Cognition* at initial 
visit
21.9 (4.0) −0.12 (1.7) −1.7 (1.6) −2.8 (1.4) 27.7 (7.3) 24.8 (6.8) 22.3 (11.8)
⫲
Follow-up time were years from the baseline BMI assessment to the last BMI assessment.
*Cognition measured by Mini-Mental State Examination (MMSE) in Predictors study and NACC. A composite cognitive Z-score[32, 52] was used 
to measure cognition in WHICAP.
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Table 3
Change of BMI over time in three cohorts, by initial BMI level*.
Predictors study Before AD onset BMIs After and on AD onset BMIs Prevalent AD BMIs
N β p N β p N β p
Underweight/ normal 95/482 0.21 0.06
Overweight 68/377 −0.06 0.59
Obese 25/154 −0.21 0.14
WHICAP Before AD onset BMIs After and on AD onset BMIs Prevalent AD BMIs
N β p N β p N β p
Underweight/ normal 62/176 −0.10 0.12 52/137 0.06 0.49 41/114 −0.002 0.97
Overweight 61/182 −0.13 0.05 50/136 −0.12 0.06 51/139 −0.07 0.51
Obese 49/140 −0.18 0.34 39/95 −0.18 0.34 23/70 −0.12 0.52
NACC Before AD onset BMIs After and on AD onset BMIs Prevalent AD BMIs
N β p N β p N β p
Underweight/ normal 260/630 −0.06 0.52 259/665 0.31 <0.0001 1297/3532 0.21 <0.0001
Overweight 237/580 −0.09 0.23 237/608 0.04 0.66 1238/3471 0.01 0.82
Obese 75/178 −0.82 <0.0001 94/216 −0.40 0.05 581/1617 −0.26 0.001
*
The analysis was based on Model 3, which was adjusted for age, gender, ethnicity, education, study center (for NACC data and Predictors study), 
plus residence (nursing home or full-term care facilities vs. home or retirement home), medication use (including both weight-gaining medicine and 
weight-losing medicine).
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